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Abstract
In 2004, a population-based cohort (the Núcleo Mama Porto Alegre - NMPOA Cohort) was started in Porto Alegre,
southern Brazil and within that cohort, a hereditary breast cancer study was initiated, aiming to determine the preva-
lence of hereditary breast cancer phenotypes and evaluate acceptance of a genetic cancer risk assessment (GCRA)
program. Women from that cohort who reported a positive family history of cancer were referred to GCRA. Of the
9218 women enrolled, 1286 (13.9%) reported a family history of cancer. Of the 902 women who attended GCRA, 55
(8%) had an estimated lifetime risk of breast cancer  20% and 214 (23.7%) had pedigrees suggestive of a breast
cancer predisposition syndrome; an unexpectedly high number of these fulfilled criteria for Li-Fraumeni-like syn-
drome (122 families, 66.7%). The overall prevalence of a hereditary breast cancer phenotype was 6.2% (95%CI:
5.67-6.65). These findings identified a problem of significant magnitude in the region and indicate that genetic cancer
risk evaluation should be undertaken in a considerable proportion of the women from this community. The large pro-
portion of women who attended GCRA (72.3%) indicates that the program was well-accepted by the community, re-
gardless of the potential cultural, economic and social barriers.
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Introduction
Latin America is formed by low-to-medium income
countries with health indicators that are evolving towards
patterns seen in developed nations. The extensive ethnic
and cultural diversity seen in these countries reflects their
history and different degrees of admixture between native
and immigrant populations. Brazil is the largest and most
populated country in Latin America, with ~170 million in-
habitants. Although Brazil has the eighth largest gross na-
tional product in the world, the average per capita income
ranks only 39
th. A significant challenge in Brazil and other
Latin American countries is the inclusion of new health
technologies,includinggeneticriskassessmentandtesting,
in health care systems that have significant budget con-
straints.
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Research ArticleThe Brazilian constitution guarantees the right to
medical assistance to every citizen and at least 75% of the
population depends almost entirely on health care provided
by the government (SUS - Sistema Único de Saúde). One
specialSUSprogramdesignedforcommunity-basedhealth
care is the Programa Saúde da Família (PSF or Family
Health program), created in the mid-90s and based upon
multidisciplinary teams composed of a physician, nurse,
1-2 nursing assistants and 4-6 lay community health work-
ers.Eachteamprovidesprimaryhealthcareforageograph-
ically defined group of approximately 600 families. The
Family Health program has expanded rapidly and currently
provides health care to about half of the population (Ra-
malho and Silva, 2000; Brasil, Ministério da Saúde, 2003a,
2003b; Harzheim et al., 2006).
With few exceptions, departments of health at city,
stateandnationallevelsdonothaveexplicitpoliciesforthe
prevention and care of people with genetic disorders. Ge-
netic services are mainly centered in teaching hospitals of
major cities and cancer genetic testing per se is not yet cov-
ered by SUS or private health insurance. In Porto Alegre,
the two existing public GCRA services are located in ter-
tiarycarecenters(Penchaszadeh,2000;Llerena,2002;Pal-
mero et al., 2007a).
Breast cancer is a significant public health problem
throughout Brazil, and is currently the first cause of can-
cer-related deaths in Brazilian women of all ages. Rio
GrandedoSul(RS),Brazil’ssouthernmoststate,hasoneof
thehighestincidencesofbreastcancerinthecountryandan
increasing breast cancer mortality rate, despite efforts to
improve the coverage for breast cancer screening (Brazil,
2003b). Breast cancer is also the leading cause of death by
cancer in young women (30-49 years) from this region
(Cadaval Gonçalves et al., 2007). The estimated incidence
for breast cancer in RS and Brazil in 2008 was 85.5 and
51.2 per 100,000, respectively (Brazilian National Cancer
Institute, 2008; Brasil, Ministério da Saúde, 2003b). Re-
cently, SUS has anticipated the recommended age at initia-
tion for annual mammographic screening from 50 to 40
years. However, routine mammographic screening is not
yet readily available.
One of the most important risk factors for breast can-
cer is a positive family history, and an estimated 5%-10%
ofalldiagnosedcasesishereditary,i.e.,causedbygermline
mutations in high penetrance predisposition genes (De la
Chapelle and Peltromaki, 1998; Offit, 1998; Margolin and
Lindblom, 2006). Germline mutations in the breast cancer
genes BRCA1 and BRCA2 are related to an increased risk
for breast, ovarian and other cancers in a syndrome known
as hereditary breast and ovarian cancer (HBOC) which ac-
counts for most cases of hereditary breast cancer (HBC)
worldwide (Miki et al., 1994; Wooster et al., 1994; Peto et
al.,1999;AnglianBreastCancerStudyGroup,2000;Anto-
niou et al., 2000, 2002). Other genes that predispose to
breast cancer, such as TP53 (associated with Li-Fraumeni
and Li-Fraumeni-like syndromes, LFS/LFL) (Li and
Fraumeni, 1969; Birch et al., 1994; Eeles, 1995) PTEN (as-
sociated with Cowden’s syndrome) (Eng, 1997) and
CHEK2(associatedwithhereditarybreastandcoloncancer
syndrome, HBCC) (Meijers-Heijboer et al., 2003) have
been identified and are thought to have important, albeit
lower, contributions to the phenotype (Li et al., 1988;
Vahteristo et al., 2002). The identification of individuals
with these syndromes is important to ensure that appropri-
ate strategies to reduce the risk of cancer are recommended
to these persons and their families (Nelson et al., 2005;
Guillem et al., 2006).
Little attention has been given to the identification
and study of hereditary breast cancer phenotypes in the
community and primary health care services (De Silva et
al., 1995; Pharoah et al., 2000; Hall et al., 2001; Hoskins et
al., 2006). In this context, the main purpose of this study
was to assess the prevalence of a significant family history
of cancer and of hereditary breast cancer phenotypes in an
underserved community with high breast cancer incidence
and mortality rates in southern Brazil.
Subjects and Methods
In April 2004, a large population-based cohort study
(the Núcleo Mama Porto Alegre - NMPOA Cohort) was
startedinPortoAlegre,thecapitalofthesouthernBrazilian
stateofRioGrandedoSul.Thecohortintendstocollectde-
mographic, epidemiologic and risk factor data from a large
sampleofwomen15yearsoldandtestamodelforcommu-
nity-based breast cancer screening for women between the
ages of 40 and 69 years, as described elsewhere (Caleffi et
al., 2009 Smith et al., 2006). Women > 15 years old who
visited primary health care units as part of the Family
Health program in seven underserved areas of Porto Alegre
were included in the NMPOA cohort from April 2004
through March 2006.
Patient recruitment
The family history of breast cancer and other tumors
was assessed in all of the patients included in the NMPOA
cohort by using a seven question instrument (Table 1) and
considered both maternal and paternal histories in first-,
second-andthird-degreerelatives.Theinstrumenthasbeen
validated for this population (manuscript submitted) (Ash-
ton-ProllaP,GiacomazziJ,SchmidtAV,RothFL,Palmero
EI, Kalakun L, Aguiar E, Moreira SM, Batassini E, Belo-
Reyes V, Caleffi M, Camey S; unpublished data) and was
basedonfeaturesassociatedwithanincreasedlikelihoodof
clinically significant BRCA mutations (Couch et al., 1997;
Shattuck-Eidens et al., 1997; Srivastava et al., 2001; Frank
et al., 2002; Nelson et al., 2005). Furthermore, a question
about the family history of breast cancer and/or colon can-
cer was included because of previous evidence indicating a
higher than expected prevalence of such an association
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Porto Alegre (Palmero et al., 2007b).
Women above the age of 18 years old who replied
positively to at least one of the questions at the primary
health care unit were referred for GCRA and invited to par-
ticipate in this study. Ethical approval (Protocol number
04-170, coordinating center IRB, Hospital de Clínicas de
Porto Alegre) was obtained from the institutions involved
and enrollment in the study required signature of informed
consent.Activerecruitmentwasinitiatedaftersixmonthsif
the patients referred by the Family Health program did not
reach NMPOA. In this case, three attempts were made to
schedule a visit by telephone, followed by a letter of invita-
tion and a search for the patient by community agents. If all
of these strategies failed, or if three scheduled appoint-
ments were not kept, no further contact was attempted.
Patient sample for weighted prevalence analysis
To determine the weighted prevalence of a hereditary
breast cancer phenotype in the population being studied,
two groups of patients were evaluated: (a) 885 unrelated
women with a family history of cancer and (b) 910 unre-
lated women of the same cohort with no family history of
cancer upon recruitment at the primary health care unit and
whowereinvitedtoparticipateinthisstudyduringtheiran-
nual mammographic screening examinations. Recruitment
was done consecutively during a period of 12 months. The
evaluation included an interview, an estimation of the risk
of breast cancer, and registration of the family history in
pedigrees of at least three generations. The presence of cri-
teria for breast cancer predisposition syndromes was as-
sessed by three clinical geneticists (PAP, FLR and CBON)
who independently reviewed each pedigree. The group of
patients referred for genetic risk evaluation was also the
group used for the validation of the seven question instru-
ment for identification of hereditary breast cancer families
(Ashton-Prolla P, Giacomazzi J, Schmidt AV, Roth FL,
Palmero EI, Kalakun L, Aguiar E, Moreira SM, Batassini
E, Belo-Reyes V, Caleffi M, Camey S; unpublished data).
Genetic cancer risk assessment (GCRA)
Genetic evaluation included recording of the medical
and family histories of each index case in detailed pedi-
grees, with information traced as far back (minimum of
three generations) and laterally as possible and including
paternal lineages. Confirmation of the family history of
cancer was attempted in all cases and pathology reports,
medical records and/or death certificates were obtained
whenever possible (unpublished data). Estimated lifetime
risksofbreastcancer(ELTR)wereobtainedbyusingClaus
tables and the Gail and Tyrer-Cuzick models (Gail et al.,
1989;Clausetal.,1994;Domcheketal.,2003;Tyreretal.,
2005). The clinical diagnosis of Hereditary Breast and
Ovarian Cancer (HBOC) Syndrome was based on the crite-
ria of the American Society of Clinical Oncology (ASCO,
1996; Ford et al., 1998). In addition, the prior probabilities
of carrying a BRCA1 or BRCA2 mutation were determined
for each patient by using mutation prevalence tables and a
modified Couch (Penn II) mutation probability model
(Frank et al., 2002; Domchek et al., 2003, 2004). All of the
pedigrees were reviewed by at least two clinical geneticists
to assess the presence of criteria for LFS, LFL, HBCC or
other cancer predisposition syndromes. For LFS, LFL and
HBCC, previously published criteria for their clinical diag-
nosis were used (Li and Fraumeni, 1969; Birch et al., 1994;
Eeles, 1995; Meijers-Heijboer et al., 2003). Three breast
cancer risk categories were established, namely, Risk
I: < 0.2 using all three models of ELTR, Risk II:  0.2 with
at least one of the models, and Risk III: women with a fam-
ily history that fulfilled the criteria for a breast cancer pre-
disposition syndrome.
Follow up
All of the patients were encouraged to perform month-
lybreastself-examinations.WomenwithELTR<0.2(Risk
I) were referred back to their primary health care unit for
prospective follow-up as determined by their age and other
non-genetic risk factors (monthly breast self-examination,
annualclinicalexamandannualmammographyforwomen
40-69 years old). Patients with ELTR  0.2 (Risk II) and
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Table 1 - Positive responses to the family history questionnaire given by 1,247 women referred to genetic cancer risk assessment (GCRA).
Question GCRA non-attenders
(n = 345)
GCRA attenders
(n = 902)
p
N% N%
Did any of your first degree relatives have breast or ovarian cancer? 122 35.4 378 42.0 0.118
Did any of your relatives have bilateral breast cancer? 48 14.1 112 12.4 0.561
Did any man in your family have breast cancer? 6 1.7 11 1.2 0.590
Did any woman in your family have breast and ovarian cancer? 47 13.9 44 4.9 < 0.001
Did any woman in your family have breast cancer before the age of 50 years? 214 62.4 568 63.0 0.551
Do you have two or more relatives with breast and/or ovarian cancer? 63 18.3 226 25.1 0.016
Do you have two or more relatives with breast and/or bowel cancer? 69 20.2 234 25.9 0.062thosewhofulfilledcriteriaforhereditarybreastcancersyn-
drome (Risk III) were referred for clinical breast evalua-
tions at 6-month intervals. In addition, for women in risk
categories II and III, a recommendation was made for an-
nualmammographyintercalatedwithbreastmagneticreso-
nance imaging at 6-month intervals; breast ultrasound was
recommended for those with very dense breasts and/or
whenever clinically indicated. Women in risk category III
began screening at the age of 25 years or as soon as a risk
was identified. Those with an increased risk for tumors
other than breast cancer were referred to tertiary care cen-
ters for inclusion in comprehensive cancer screening pro-
grams. Those with criteria for a breast cancer predisposi-
tion syndrome were offered genetic testing and the results
of this investigation will be described elsewhere.
After conclusion of the genetic evaluation, written re-
ports and a brochure with key information about the preva-
lence, treatment and prevention of breast cancer, as well as
information about hereditary breast cancer, were mailed to
all of the patients. The vast majority of the women included
in this study relied exclusively upon the public health care
system.Althoughmammographicscreeningandclinicalfol-
low-up are available in this system outside the cohort study
described here, access to these facilities is limited and most
women would not have been able to comply with the recom-
mendedscreeningguidelinesiftheyhadnotbeenincludedin
this study. Magnetic resonance imaging of the breast is not
routinely available in the public health care system.
Statistical analysis
Quantitative variables were expressed as the mean 
SD, whereas categorical variables (descriptive analyses)
were recorded as absolute and/or relative frequencies. The

2 test was used to compare the distribution of the answers
to the family history questionnaire between attenders and
non-attenders, whereas ANOVA was used to compare the
mean values of the risk estimates and the history of breast
cancer among the different risk categories. Kappa coeffi-
cients were used to assess the agreement between results
provided by the instrument and the estimated genetic can-
cer risk. The weighted prevalence of hereditary breast can-
cer phenotypes was calculated using the following
weighting: group with a family history of cancer
(885/1285) and group with no family history of cancer
(910/7933). All data handling and statistical analyses were
done using the statistical software package SPSS (version
14.0), and a value of p < 0.05 indicated significance.
Results
Description of the population served by the program
The women enrolled in this study were residents of
seven regions in Porto Alegre. These regions correspond to
64%ofthetotalareaofthecityand~35%ofitspopulation.
All women relied almost exclusively on the Family Health
Program for health care. Although specific demographic
data for this population of the Family Health Program cli-
ents was unavailable, data from the most recent municipal
census indicate that 49.2% of the inhabitants in these re-
gions have < 8 years of education (5.6% are illiterate), 20%
liveintemporaryhomesand6.5%offamilyprovidershave
no income (Porto Alegre, Prefeitura Municipal 2004).
Patient recruitment
Of the 9218 women enrolled in the cohort, 1286
(13.9%) answered positively to at least one of the seven
questions about a family history of cancer (Figure 1) and
those above the age of 18 years old (n = 1247) were referred
for GCRA. Of these, 260 (21%) did not reach NMPOA and
did not respond to the active recruitment strategies within a
12 month period after inclusion in the cohort. In addition, 41
(3.3%)womenscheduledanappointmentthreetimesbutdid
not show up, and another 43 (3.4%) did not wish to partici-
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Figure 1 - Preliminary results of genetic cancer risk assessment in a popu-
lation-based cohort of women > 15 years of age in Porto Alegre, Brazil.
GCRA – genetic cancer risk assessment; FH – family history; BC – breast
cancer;OC–ovariancancer;CRC–colorectalcancer;BCPS–breastcan-
cer predisposition syndrome; HBCC – hereditary breast and colorectal
cancer syndrome; LFL – Li-Fraumeni-like syndrome; HBOC – hereditary
breast and ovarian cancer syndrome.pate in the study. The remaining 902 women from 829 fami-
lies were compliant with the referral and attended GCRA.
The demographic data of women with a positive fam-
ily history who underwent GCRA (attenders) differed sig-
nificantly in some aspects from those of women who did
not undergo GCRA (non-attenders). Non-attenders were
generally younger, less educated, and had undergone a
breastbiopsylessoftenthanattenders(p<0.001).Formost
of the questions in the family history questionnaire, there
was no significant difference between the proportion of
positive answers between attenders and non-attenders. Ex-
ceptions to this included: (a) the question about a family
history of breast and/or ovarian cancer in  2 relatives, for
which attenders provided a greater number of positive an-
swers, and (b) the question about the combined occurrence
of breast and ovarian cancer in a relative, for which
non-attenders provided a greater number of positive an-
swers(Table1).Thelatterobservationmayreflectabiasof
ascertainment with consequent deficiency in providing
GCRA to some individuals with a high risk of HBOC.
However, when the answers to this question (family mem-
ber with multiple tumors) at the primary health care unit
were compared to the family history reported by attenders
during GCRA, and confirmed by review of medical re-
cords, there was low agreement between the responses ob-
served, i.e. only one diagnosis (usually breast cancer)
remained in most cases (Kappa coefficient = 0.069).
Risk assessment
Table 2 summarizes the demographic and other vari-
ables related to the estimation of lifetime risk for develop-
ing breast cancer in the 902 attenders. A significant propor-
tion of the women were smokers and overweight or obese,
as also observed in the NMPOA cohort as a whole (Caleffi
et al., 2009). A high number of patients reported a positive
family history for cancer in the maternal lineage: 26.1%
had a family history of breast cancer only, whereas 19.8%
had a family history of breast cancer and colorectal cancer
(CRC). Most of the women evaluated (688, 76.3%) did not
fulfill criteria for breast cancer predisposition syndromes.
Among these women, the estimated lifetime risk of devel-
oping breast cancer was < 0.2 in 633 (92%) and  0.2 in 55
(8%). The most common feature of the family history that
justified GCRA in this group of patients was the presence
ofarelativewithbreastcancerwhowas<50yearsold(Ta-
ble 3). The remaining 214 women (23.7%) from 183 fami-
lies had pedigrees suggestive of breast cancer predisposi-
tion syndrome. Of these 183 families, the majority fulfilled
criteria for the Li-Fraumeni-like syndrome (Figure 1). The
overall weighted prevalence of a breast cancer predisposi-
tion syndrome phenotype in the sample studied was 6.2%.
Twenty-five families fulfilled criteria for more than one
syndrome.The76patients(65families)whofulfilledcrite-
ria for HBOC syndrome had average BRCA mutation prob-
abilities of 21.9  13.9% and 25.7  14.8% by the Penn II
model and BRCA mutation prevalence tables, respectively.
For all of the attenders who were unaffected by cancer, the
ELTR estimates obtained using the Claus tables and the
Gail and Tyrer-Cuzick models were 13.6%, 13.9% and
13.9%,respectively.Table3summarizesthefamilyhistory
ofbreastcancerandELTRdataforpatientsinthethreerisk
categories.
Discussion
By using a simple seven-question instrument to in-
quireaboutthefamilyhistoryofcancerinwomenfrompri-
mary health care units of an underserved region in southern
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Table2-Demographicdataandcharacteristicsofthe902womenwhoun-
derwent genetic cancer risk assessment (GCRA)
N % Mean SD
Age at assessment (yr) - - 43.2 12.7
BMI 27.9 5.8
 18.5 6 0.7 - -
18.51-25 300 33.3 - -
25.01-30 298 33.0 - -
> 30 285 31.6 - -
Smoking 262 29.0 - -
Age at menarche - - 12.7 1.7
Parity
No children 108 12.0 - -
One or more children 790 88.0 - -
Age at birth of first child - - 21.5 5.0
Reproductive status
Pre-menopausal 585 65.2 - -
Post-menopausal 312 34.8 - -
Age at menopause - - 47.0 5.4
Endogenous hormone exposure (yr) - - 27.3 9.7
Hormone replacement therapy 73 8.1 -
Consanguinity* 65 7.3 -
Family history of cancer
Side of family
Maternal 554 62.7 - -
Paternal 223 25.2 - -
Maternal and paternal 58 6.6 - -
Others (siblings/offspring) 49 5.5 - -
Breast cancer family history
Breast cancer only 234 26.1 - -
Breast and ovarian cancer 87 9.6 - -
Breast and colon cancer 179 19.8 - -
BMI = body mass index; yr = years.
The number of respondents varied because of missing information for
some variables.
*Evidence of consanguinity within the family, regardless of the relation-
ship to the proband.Brazil, we identified a significant proportion with family
histories of cancer who fulfilled criteria for one of the most
commonly recognized hereditary breast cancer syndromes.
Theoverallprevalence(6.2%)wassimilartothatdescribed
in other population-based samples, although only a few
studies have addressed this issue to date (Pharoah et al.,
2000; Hughes et al., 2003; Palomaki et al., 2006). Most of
the families with hereditary breast cancer phenotypes cor-
responded to LFL syndrome. Although there is a pheno-
typic overlap among the HBOC, LFS/LFL and HBCC
syndromes, the high frequency of LFL pedigrees observed
here is striking, especially considering that the original
questionnaire used to identify these patients was not de-
signed to screen for LFS/LFL.
Already ten years ago (Varley et al., 1999) described
certain low penetrance TP53 alleles and suggested that del-
eterious mutations in TP53 (or related genes) may be more
frequent in the population than previously estimated. In ad-
dition, several recent reports have indicated that a deleteri-
ous germline mutation in TP53, R337H, might be very
prevalent and related to a founder effect in southern Brazil
(Pinto et al., 2004; Achatz et al., 2007; Palmero et al.,
2008). Although some of the criteria used here to diagnose
the LFL phenotype were not stringent (i.e. Eeles criteria
used to classify LFL phenotype) and may have little sensi-
tivity for identifying germline TP53 mutations in other
countries, the unexpectedly high number of criteria-
positive patients suggests that LFL may indeed be a com-
mon phenotype for hereditary breast cancer in and around
PortoAlegre.Futureresultsfromgermlinemutationtesting
shouldhelptoclarifythisissueandcontributetoourunder-
standing of the applicability and discriminatory capacity of
breastcancerriskestimationmodels,currentdiagnosticcri-
teria and mutation prediction models for hereditary breast
cancer syndromes in this population. If such a high preva-
lence of LFS/LFL syndrome is confirmed among families
in this geographic area, an effort will have to be made to fa-
cilitate the identification of high-risk individuals and delin-
eate effective cancer screening and prevention programs in
these subjects.
The relatively large proportion of women (72.3%)
who attended the proposed GCRA was very encouraging
and comparable to that encountered in similar studies, e.g.,
88% and 70% in underserved communities in the U.S.A.
(Ricker et al., 2006) and Singapore (Chin et al., 2005), re-
spectively. Furthermore, in a recent study by ONeill et al.
(2006) in the U.S.A., the outcome of genetics referrals was
evaluatedinagroupofwomenwithestimatedBRCAmuta-
tion probabilities  10%. Within six-months after referral,
36% of the patients had undergone genetic evaluations (ac-
ceptors), 27% still intended to seek (intenders) and 36% re-
fused such assessment (decliners). Population-based
mammographic screening programs worldwide have also
reported compliance rates of 61%-83% (Banks et al., 2002;
O’Malley et al., 2002; Finney et al., 2006).
Inthisstudy,thenumberofattendersalsohastobein-
terpreted in light of the difficulties that most of these
women face to seek advice, health care and cancer preven-
tion opportunities. First, there might be a cultural differ-
enceincancer-associatedriskperceptionand/oradifficulty
in understanding the impact of preventive interventions.
The way of dealing with risk is not only influenced by risk
perception but also by culture. This was clearly demon-
strated by Hofstede (1997) in a landmark study in which
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Table 3 - Risk estimates and breast cancer history according to risk category in the 902 women who underwent genetic risk assessment.
Estimated lifetime risk for
breast cancer < 0.2
(n = 633)
Estimated lifetime risk for
breast cancer  0.2
(n = 55)
Phenotype of breast cancer
predisposition syndrome
(n = 214)
p
Number of BC cases in family* 0.98  0.67 1.45  0.83 1.69  1.14 < 0.001
Number of BC-affected generations* 0.92  0.54 1.24  0.55 1.29  0.64 < 0.001
Average age (yr) at BC diagnosis in the family 46.6  10.6 47.0  11.4 46.6  11.2 0.968
ELTR for BC
Using the Gail model** 10.2  4.1 19.2  5.1 12.3  6.6 < 0.001
Using the Claus model* 10.2  2.8 16.7  7.8 13.9  7.4 < 0.001
Using the Tyrer-Cuzick model** 9.8  3.7 19.6  6.2 12.4  5.6 < 0.001
Prior probability of mutation in a BRCA gene
Mutation prevalence tables*** 6.3  3.8 6.7  3.9 13.2  13.0 < 0.001
Modified Couch model*** 9.7  4.3 10.3  5.0 14.8  10.6 < 0.001
The values are the mean  SD. BC = breast cancer, BCPS = breast cancer predisposition syndrome, ELTR = estimated lifetime risk.
*The mean value of the group with a slightly increased risk was significantly lower than that of the other two groups.
**The mean values in all three groups differed significantly from each other.
***The mean value of the group that had criteria for breast cancer predisposition syndrome was significantly greater than that of the other two groups.
Note:ThenumberofvalidcasesusedineachoftheELTRandpriorprobabilityanalyseswas878,592and874fortheGail,ClausandTyrer-Cuzickmod-
els, respectively. For the mutation prevalence tables and the modified Couch model, 890 and 874 valid cases were used, respectively.different cultures around the world were characterized
based on five parameters, including the uncertainty avoid-
ance index (UAI). This index, which reflects the
tolerability of a given society towards uncertainty and am-
biguity, is higher in Brazil than in Denmark, the United
Kingdom and the U.S.A. Such differences could interfere
with cancer risk perception and motivation to seek GCRA.
Inaddition,certainculturesaremorefatalisticaboutcancer
and perceive fewer benefits from screening (Russell et al.,
2006). Second, there may be a knowledge barrier in under-
standing how preventive measures will ultimately increase
quality of life (Achat et al., 2005; Ricker et al., 2006;
Farmer et al., 2007). Third, in many of these women, care
of themselves is often set aside because of more urgent
needs, such as providing food, housing and education for
their families. Fourth, it may be that these women are sim-
plyobeyingandrespectingahierarchicalstructureinwhich
they attend GCRA only because they are told to do so, and
their cultural conditioning generally makes them follow
health recommendations once they are given. Finally, there
has been a historical lack of resources to ensure that ade-
quate screening is provided in this area, even if there is evi-
dence for a higher risk (Smith et al., 2006). Consequently,
most of these women may have seen the program offered
here as an opportunity to be grasped since they would oth-
erwise face significant difficulties in following standard
recommendations for breast cancer screening if they relied
solely upon the public health care system.
For all of these reasons, programs such as that de-
scribed here, which attempt to identify and prospectively
follow women with an increased risk of cancer, need to
consider the importance of patient education and social in-
terventions (i.e., facilitate transportation, nutrition and
childcare)inthedifficulttaskofmaintainingcomplianceto
the recommended guidelines. A more detailed study of
non-attenders may provide better clues on how to improve
coverage for programs such as these, thereby ensuring that
most high-risk patients have access to the information and
preventive interventions they require.
In conclusion, the implementation of a GCRA pro-
gram for an underserved community in southern Brazil re-
vealed that the overall prevalence of a hereditary breast
cancerphenotypeinthispopulation-basedsampleofwomen
was 6.2%, which may be a matter of considerable concern in
this region. In addition, the establishment of breast cancer
risk categories allowed the identification of higher risk
womenwhomaybenefitfrommoreintensivescreening.The
relatively high number of women who attended GCRA ses-
sions after an initial referral suggested that the program was
well accepted by the community and is feasible, regardless
of potential cultural, economic and social barriers.
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